This month’s editorial looks beyond treatment efficacy for haematological malignancies to how adverse effects persist and accumulate in patients’ daily lives, exploring toxicity beyond maximum grade through long-term effects, regulatory considerations, and real-world digital health technologies. This also highlights the importance of listening to patients’ experiences and feedback.